Inhibrx Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California. The company was founded in 2010 and is focused on developing and commercializing novel protein therapeutics for the treatment of life-threatening diseases.
Inhibrx's proprietary single-domain antibody platform allows the company to create targeted therapies that are more effective and less toxic than traditional antibody-based therapies. The company's pipeline includes a number of promising candidates for the treatment of diseases such as alpha-1 antitrypsin deficiency (AATD), cystic fibrosis, and cancer.
Inhibrx has a strong team of experienced scientists and executives with a proven track record in the biotechnology industry. The company has raised over $200 million in funding and has a number of strategic partnerships with leading pharmaceutical companies.
Inhibrx is committed to developing innovative therapies that improve the lives of patients with life-threatening diseases. The company is advancing its pipeline through a combination of in-house research and development and strategic partnerships. Inhibrx is also committed to providing patients with access to its therapies through a variety of commercialization strategies.
Inhibrx is a well-funded and well-positioned company with a promising pipeline of therapeutic candidates. The company is expected to make significant progress in the development and commercialization of its therapies in the coming years.